News
-
NeuroDerm Announces Positive Results Of A Phase I Study Of ND0612 For The Treatment Of Parkinson's Disease
3/4/2013
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously sub-cutaneously through a patch pump. It is designed to provide steady levodopa blood levels for the reduction of motor complications in Parkinson's disease. Results of this study support the continued development of ND0612 for the treatment of Parkinson's disease.
-
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial
2/19/2013
Concert Pharmaceuticals, Inc. announced today that it has completed enrollment of patients in a Phase 2 clinical trial evaluating CTP-499 for the treatment of diabetic kidney disease. CTP-499 is intended to slow progression of kidney damage in diabetic kidney disease and be additive to the current standard of care, which is treatment with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin receptor blocker (ARB). Concert expects to report top-line results from the Phase 2 study during the second-half of 2013.
-
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5M Milestone Payment From GlaxoSmithKline
2/19/2013
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study for ISIS-TTRRx.
-
New Study On Emerging Markets Reports Low Marks For Asia
2/6/2013
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, completed an analysis of recent clinical work in Emerging Markets.
-
Theravance Announces Initiation Of Phase 2b Study With Its LAMA Candidate, TD-4208, For The Treatment Of COPD
12/11/2012
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD.
-
Peregrine Pharmaceuticals Announces Significant Progress In Advancing Its Cotara Program Into A Pivotal Phase III Trial
12/5/2012
Peregrine Pharmaceuticals (
NASDAQ : PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement with the U.S. -
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, In Patients With Epilepsy
12/3/2012
Upsher-Smith Laboratories, Inc., (Upsher-Smith) announced that Phase I data for USL261 (intranasal midazolam) in patients with epilepsy were presented at the American Epilepsy Society Annual Meeting in San Diego, CA.
-
Isis Announces Expedited Development Of ISIS-TTR Rx And Amendment To The Collaboration With GSK To Support Phase 2/3 Study
11/5/2012
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Isis and GlaxoSmithKline (NYSE: GSK) have agreed to amend the clinical development plan and financial terms relating to ISIS-TTRRx to reflect the accelerated development plan for the drug. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of TTR amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerves and/or heart tissue.
-
INC Research Discusses Benefits Of Involving CROs Early In Planning At Partnerships In Clinical Trials 2012
11/5/2012
INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process for delivering reliable results, will discuss the importance of involving CROs early in the planning process at the Partnerships in Clinical Trials conference, November 6-9, 2012 at the CCH Congress Center in Hamburg, Germany.
-
Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
11/1/2012
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).